Tags

Type your tag names separated by a space and hit enter

Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer.
Chin Med J (Engl). 2016 12 05; 129(23):2868-2872.CM

Abstract

OBJECTIVE

To review the prevalence and prognostic significance of fibroblast growth factor receptor 1 (FGFR1) amplification and to establish an association between FGFR1 amplification and the clinical characteristics of nonsmall cell lung cancer (NSCLC).

DATA SOURCES

We searched PubMed for English-language studies published between January 2010 and May 2016.

STUDY SELECTION

We included all relevant articles, with no limitation of study design.

RESULTS

FGFR1 amplification was reported in 8.7-20.0% of NSCLC cases and was significantly more frequent in squamous cell carcinomas (SCCs) (9.7-28.3%) than in adenocarcinomas (ADCs) (0-15.0%). The rates of FGFR1 amplification were as follows: males, 13.9-22.1%; females, 0-20.1%; Stage I NSCLC, 9.3-24.1%; Stage II NSCLC, 12.9-25.0%; Stage III NSCLC, 8.2-19.5%; Stage IV NSCLC, 0-12.5%; current smokers, 13.3-29.0%; former smokers, 2.5-23.0%; and nonsmokers, 0-22.2%. Overall survival was 43.9-70.8 months in patients with FGFR1 amplification and 42.4-115.0 months in patients with no FGFR1 amplification; disease-free survival was 22.5-58.5 months and 52.4-94.6 months, respectively.

CONCLUSIONS

FGFR1 amplification is more frequent in SCCs than in ADCs. The association between FGFR1 amplification and clinical characteristics (gender, smoking status, and disease stage) and the prognostic significance of FGFR1 amplification in NSCLC remain controversial.

Authors+Show Affiliations

Department of Respiratory Medicine, Shandong Jining No. 1 People's Hospital, Jining, Shandong 272000, China.Department of Respiratory Medicine, Shandong Jining No. 1 People's Hospital, Jining, Shandong 272000, China.Department of Respiratory Medicine, Shandong Jining No. 1 People's Hospital, Jining, Shandong 272000, China.Zouping County Institute for Tuberculosis Prevention and Control, Binzhou, Shandong 256200, China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27901003

Citation

Miao, Jian-Long, et al. "Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer." Chinese Medical Journal, vol. 129, no. 23, 2016, pp. 2868-2872.
Miao JL, Liu RJ, Zhou JH, et al. Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer. Chin Med J (Engl). 2016;129(23):2868-2872.
Miao, J. L., Liu, R. J., Zhou, J. H., & Meng, S. H. (2016). Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer. Chinese Medical Journal, 129(23), 2868-2872. https://doi.org/10.4103/0366-6999.194649
Miao JL, et al. Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer. Chin Med J (Engl). 2016 12 5;129(23):2868-2872. PubMed PMID: 27901003.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer. AU - Miao,Jian-Long, AU - Liu,Rui-Juan, AU - Zhou,Jin-Hua, AU - Meng,Shu-Hua, PY - 2016/12/1/entrez PY - 2016/12/3/pubmed PY - 2017/7/14/medline SP - 2868 EP - 2872 JF - Chinese medical journal JO - Chin Med J (Engl) VL - 129 IS - 23 N2 - OBJECTIVE: To review the prevalence and prognostic significance of fibroblast growth factor receptor 1 (FGFR1) amplification and to establish an association between FGFR1 amplification and the clinical characteristics of nonsmall cell lung cancer (NSCLC). DATA SOURCES: We searched PubMed for English-language studies published between January 2010 and May 2016. STUDY SELECTION: We included all relevant articles, with no limitation of study design. RESULTS: FGFR1 amplification was reported in 8.7-20.0% of NSCLC cases and was significantly more frequent in squamous cell carcinomas (SCCs) (9.7-28.3%) than in adenocarcinomas (ADCs) (0-15.0%). The rates of FGFR1 amplification were as follows: males, 13.9-22.1%; females, 0-20.1%; Stage I NSCLC, 9.3-24.1%; Stage II NSCLC, 12.9-25.0%; Stage III NSCLC, 8.2-19.5%; Stage IV NSCLC, 0-12.5%; current smokers, 13.3-29.0%; former smokers, 2.5-23.0%; and nonsmokers, 0-22.2%. Overall survival was 43.9-70.8 months in patients with FGFR1 amplification and 42.4-115.0 months in patients with no FGFR1 amplification; disease-free survival was 22.5-58.5 months and 52.4-94.6 months, respectively. CONCLUSIONS: FGFR1 amplification is more frequent in SCCs than in ADCs. The association between FGFR1 amplification and clinical characteristics (gender, smoking status, and disease stage) and the prognostic significance of FGFR1 amplification in NSCLC remain controversial. SN - 2542-5641 UR - https://www.unboundmedicine.com/medline/citation/27901003/Fibroblast_Growth_Factor_Receptor_1_Gene_Amplification_in_Nonsmall_Cell_Lung_Cancer_ L2 - https://doi.org/10.4103/0366-6999.194649 DB - PRIME DP - Unbound Medicine ER -